|
|
基于网络药理学和分子对接技术探索降脂通脉胶囊抗动脉粥样硬化作用机制
|
Abstract:
目的：运用网络药理学方法探讨降脂通脉胶囊抗动脉粥样硬化(atherosclerosis, AS)的潜在分子机制，为后续开展实验研究提供生物信息学基础。方法：通过TCMSP、HERB、CTD数据库及已有文献查找降脂通脉胶囊药物活性成分与靶点。利用Cytoscape软件构建“中药–有效成分–靶点”网络。通过Gene Cards数据库查找动脉粥样硬化相关靶点。利用Venny 2.1获取重合靶点。重合靶点上传于String 11.0平台进行蛋白质相互作用分析并及可视化呈现，于OmicShare云平台进行GO功能和KEGG通路富集分析。结果：共筛选出31个活性成分，活性成分作用靶点共248个。活性成分作用靶点与AS靶点共重合186个。GO富集分析得到生物过程6249个，分子功能967个。KEGG通路分析结果显示靶点富集于261条通路上，其中包含PI3K-Akt信号通路、流体剪切应力与动脉粥样硬化等AS关键的通路。结论：降脂通脉胶囊包含多个活性成分，其可通过多靶点、多通路的方式抗动脉粥样硬化，体现出中医药抗AS的多靶优势。
Objective: This study was to explore the potential molecular mechanism of Jiangzhi Tongmai Cap-sules anti-atherosclerosis (AS) by using network pharmacology, providing a bioinformatics basis for subsequent experimental research. Methods: The active ingredients and targets of Jiangzhi Tongmai capsules were collected through TCMSP, HERB, CTD databases and literatures. Cytoscape software was used to construct a “traditional Chinese medicine-active ingredient-target” network. The atherosclerosis-related genes were collected through the Gene Cards database. Venny 2.1 was used to obtain the overlapping targets. The overlapping targets were uploaded on the String 11.0 platform for protein-protein interaction analysis and graphical visualization. The GO function and KEGG pathway enrichment analysis was performed on the OmicShare platform. Results: A total of 31 active ingredients were screened, and 248 corresponding targets were obtained. A total of 186 targets were overlapped between the targets for active ingredient and AS-related genes. GO enrich-ment analysis obtained 6249 biological processes and 967 molecular functions. The results of KEGG pathway analysis showed that the targets were enriched in 261 pathways, including PI3K-Akt sig-naling pathway, fluid shear stress and atherosclerosis. Conclusion: Jiangzhi Tongmai Capsule con-tains multiple active ingredients, which can resist atherosclerosis through multiple targets and pathways, reflecting the multi target advantage of traditional Chinese medicine in anti-AS.
| [1] | Kobiyama, K. and Ley, K. (2018) Atherosclerosis. Circulation Research, 123, 1118-1120.
https://doi.org/10.1161/CIRCRESAHA.118.313816 |
| [2] | Zhao, D., Liu, J., Wang, M., Zhang, X. and Zhou, M. (2019) Epidemiology of Cardiovascular Disease in China: Current Features and Implications. Nature Reviews Cardiology, 16, 203-212. https://doi.org/10.1038/s41569-018-0119-4 |
| [3] | Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. (2014) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63, 2889-2934. https://doi.org/10.1016/j.jacc.2013.11.002 |
| [4] | Falk, E. (2006) Pathogenesis of Atherosclerosis. Journal of the American College of Cardiology, 47, C7-C12.
https://doi.org/10.1016/j.jacc.2005.09.068 |
| [5] | Pedro-Botet, J., Climent, E. and Benaiges, D. (2020) Atheroscle-rosis and Inflammation. New Therapeutic Approaches. Medicina Clínica, 155, 256-262. https://doi.org/10.1016/j.medcli.2020.04.024 |
| [6] | Singh, M. and Bedi, U.S. (2013) Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean? Current Atherosclerosis Reports, 15, Article No. 294. https://doi.org/10.1007/s11883-012-0294-4 |
| [7] | Wang, C., Niimi, M., Watanabe, T., et al. (2018) Treatment of Atherosclerosis by Traditional Chinese Medicine: Questions and Quandaries. Atherosclerosis, 277, 136-144. https://doi.org/10.1016/j.atherosclerosis.2018.08.039 |
| [8] | 卢火木. 降脂通脉胶囊联合辛伐他汀治疗高脂血症的效果及安全性分析[J]. 中外医学研究, 2021, 19(35): 135-138. |
| [9] | 王武玲, 严福建, 徐明丽, 高晨. 降脂通脉胶囊联合常规疗法治疗非酒精性脂肪性肝炎临床研究[J]. 新中医, 2021, 53(3): 73-76. |
| [10] | 饶春燕, 张祥, 胡建华. 降脂通脉胶囊对痰瘀互结型高脂血症患者的临床疗效观察[J]. 中成药, 2015, 37(6): 1388-1390. |
| [11] | 散兴忠, 赵俊, 戢运建. 降脂通脉胶囊治疗颈动脉硬化的疗效观察[J]. 现代中西医结合杂志, 2011, 20(7): 831-832. |
| [12] | 陈宏. 降脂通脉胶囊对冠心病患者颈动脉粥样硬化斑块的影响[J]. 中西医结合心脑血管病杂志, 2013, 11(8): 935-936. |
| [13] | Nogales, C., Mamdouh, Z.M., List, M., et al. (2022) Network Pharmacology: Curing Causal Mechanisms Instead of Treating Symptoms. Trends in Pharmacological Sciences, 43, 136-150. https://doi.org/10.1016/j.tips.2021.11.004 |
| [14] | Pescetelli, I., Zimarino, M., Ghirarduzzi, A. and De Caterina, R. (2015) Localizing Factors in Atherosclerosis. Journal of Cardiovascular Medicine, 16, 824-830. https://doi.org/10.2459/JCM.0000000000000224 |
| [15] | Libby, P., Bornfeldt, K.E. and Tall, A.R. (2016) Athero-sclerosis: Successes, Surprises, and Future Challenges. Circulation Research, 118, 531-534. https://doi.org/10.1161/CIRCRESAHA.116.308334 |
| [16] | Barton, M. (2013) Mechanisms and Therapy of Athero-sclerosis and Its Clinical Complications. Current Opinion in Pharmacology, 13, 149-153. https://doi.org/10.1016/j.coph.2013.05.001 |
| [17] | Amirkia, V. and Heinrich, M. (2015) Natural Products and Drug Discovery: A Survey of Stakeholders in Industry and Academia. Frontiers in Pharmacology, 6, Article 237. https://doi.org/10.3389/fphar.2015.00237 |
| [18] | Heo, S.K., Yun, H.J., Park, W.H. and Park, S.-D. (2009) Rhein In-hibits TNF-α-Induced Human Aortic Smooth Muscle Cell Proliferation via Mitochondrial-Dependent Apoptosis. Journal of Vascular Research, 46, 375-386.
https://doi.org/10.1159/000189798 |
| [19] | Zhong, X.F., Huang, G.D., Luo, T., Deng, Z.-Y. and Hu, J.-N. (2012) Protective Effect of Rhein against Oxidative Stress-Related Endothelial Cell Injury. Molecular Medicine Reports, 5, 1261-1266. |
| [20] | Tang, X., Zhang, Y., Liu, X., et al. (2022) Aloe-Emodin Derivative Produces Anti-Atherosclerosis Effect by Reinforcing AMBRA1-Mediated Endothelial Autophagy. European Journal of Pharmacology, 916, Article ID: 174641.
https://doi.org/10.1016/j.ejphar.2021.174641 |
| [21] | Li, H., Xiao, L., He, H., et al. (2021) Quercetin Attenuates Ath-erosclerotic Inflammation by Inhibiting Galectin-3-NLRP3 Signaling Pathway. Molecular Nutrition & Food Research, 65, e2000746. https://doi.org/10.1002/mnfr.202000746 |
| [22] | Sato, S. and Mukai, Y. (2020) Modulation of Chronic Inflammation by Quercetin: The Beneficial Effects on Obesity. Journal of Inflammation Research, 13, 421-431. https://doi.org/10.2147/JIR.S228361 |
| [23] | Luo, Y., Shang, P. and Li, D. (2017) Luteolin: A Flavonoid That Has Multiple Cardio-Protective Effects and Its Molecular Mechanisms. Frontiers in Pharmacology, 8, Article 692. https://doi.org/10.3389/fphar.2017.00692 |
| [24] | Ma, L., Ballantyne, C.M., Belmont, J.W., Keinan, A. and Brautbar, A. (2012) Interaction between SNPs in the RXRA and Near ANGPTL3 Gene Region Inhibits apoB Reduction after Statin-Fenofibric Acid Therapy in Individuals with Mixed Dyslipidemia. Journal of Lipid Research, 53, 2425-2428. https://doi.org/10.1194/jlr.M028829 |
| [25] | Linton, M.F., Moslehi, J.J. and Babaev, V.R. (2019) Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis. International Journal of Molecular Sciences, 20, Article No. 2703. https://doi.org/10.3390/ijms20112703 |
| [26] | McNair, E., Qureshi, M., Prasad, K., et al. (2016) Atherosclero-sis and the Hypercholesterolemic AGE-RAGE Axis. International Journal of Angiology, 25, 110-116. https://doi.org/10.1055/s-0035-1570754 |
| [27] | Jandeleit-Dahm, K., Watson, A. and Soro-Paavonen, A. (2008) The AGE/RAGE Axis in Diabetes-Accelerated Atherosclerosis. Clinical and Experimental Pharmacology and Physiology, 35, 329-334.
https://doi.org/10.2174/0929867324666170419150614 |
| [28] | Lu, X. (2017) The Impact of IL-17 in Atherosclerosis. Current Medicinal Chemistry, 24, 2345-2358.
https://doi.org/10.2174/0929867324666170419150614 |
| [29] | Ridker, P.M. (2019) Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circulation Research, 124, 437-450. https://doi.org/10.1161/CIRCRESAHA.118.313129 |
